Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
Lin Shen(Hangzhou Normal University), Lin Xie, Wenxiang Dai(First Affiliated Hospital of University of South China), Jun Zhao(Marine Biomedical Research Institute of Qingdao), Hongming Pan, Yi Ba(Tianjin Medical University Cancer Institute and Hospital), Zengqing Guo(Fujian Provincial Cancer Hospital), Futong Zhang(First Hospital of Shijiazhuang), Hao Liu(National University of Defense Technology), Jia Wei(North Sichuan Medical University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Wensheng Qiu(Qingdao University), Zhenghua Wang(Affiliated Hospital of Jining Medical University), Mulin Liu(National Yang Ming Chiao Tung University), Peng Nie(Huawei Technologies (China)), Yusheng Wang(Shanxi Provincial Cancer Hospital), Ning Li(Henan Cancer Hospital), Wěi Li(Shougang (China)), Jian Chen(Fudan University), Xiangyu Gao(Shenyang Agricultural University), Yuan Yuan(Xuzhou Central Hospital), Ming Liu(Sichuan University), Lian Liu(Qilu Hospital of Shandong University), Ye Chen(First Affiliated Hospital of Henan University of Science and Technology), Bo Liu(Northeast Petroleum University), Zheng Liu(Tongji Hospital), Yang Fu(Central South University), Ziyu Li(Peking University), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Changzheng Li(Henan Medical University), Weibo Wang(Tianjin University), Jinhong Xu, Ruixing Zhang(Hebei Medical University), Yifu He(Anhui Provincial Hospital), Jun Guo(Hebei Medical University), Xiaotian Zhang(Peking University), Yuansong Bai(First Bethune Hospital of Jilin University), Lili Sheng(First Affiliated Hospital of Wannan Medical College), Xuehong Zhao(Xian Central Hospital), Hongyan Xu(Weihai Municipal Hospital), Bangwei Cao(Capital Medical University), Zhenyang Liu(Qingdao University), Guowu Wu(Meizhou City People's Hospital), Huiting Xu(Weihai Municipal Hospital), Yanqiao Zhang(Harbin Medical University), Nong Xu(First Affiliated Hospital Zhejiang University), Lixin Wan(Nanyang Institute of Technology), Mingzhu Huang(Shanghai Medical College of Fudan University), Xizhi Zhang(People's Hospital of Kaizhou District), Kangsheng Gu(Anhui Medical University)
Cited by 2
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
HIF-1α pathway: role, regulation and intervention for cancer therapy
|Acta Pharmaceutica Sinica B|2015|1.9k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA
|Cell Research|2011|1.2k
CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
|Molecular Cancer|2020|1k